No Dice

The Wall Street Journal's Deal Book wonders why there are so few deals going on in Europe's biopharma arena -- $137 billion of health-care deals have gone down so far this year in the US. It's not for lack of trying. "One potential deal after another has fallen apart," the article says, citing companies such as Nycomed, Crucell, and Actavis that have explored sales only to have them fall through.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.